Meyenburg Symposium and Cancer Research Award Presentation to Michel Sadelain

Dear colleagues, We are excited to invite you to this year’s Meyenburg Cancer Research Award ceremony, honoring Dr. Michel Sadelain, a visionary who transformed patients’ cells into “living drugs” that fight cancer. Dr. Sadelain’s groundbreaking work on chimeric antigen receptor (CAR) T-cell therapy has fundamentally changed how we treat certain cancers. From the initial concept to FDA approval in 2017, his journey represents one of the most significant breakthroughs in modern oncology – giving hope to patients who previously had none. (See below for more information about Michel Sadelain and his work.) Please join us for the Meyenburg Symposium and Award Ceremony at the German Cancer Research Center (DKFZ) in Heidelberg on April 2, 2025 at 3:30 p.m. Speakers include: • Michel Sadelain • Andreas Mackensen (Erlangen University Hospital) • Fabrice André (Institut Gustave Roussy) • Hafsa Munir (DKFZ & Helmholtz Institute for Translational Oncology Mainz) • Franziska Blaeschke (DKFZ & Hopp Children's Cancer Center Heidelberg) Details of the program and registration (until March 28) can be found here: indico.dkfz.de/e/MeyenburgCancerResearchAward2025 We look forward to your participation. Very best wishes, Stefan Fröhling On behalf of the Board of the Meyenburg Foundation Dr. Marion Meyenburg Dr. Jörg Barth, Boehringer Ingelheim Prof. Christiane Opitz, DKFZ Prof. Stefan Pfister, DKFZ About Michel Sadelain: Revolutionary Science Meets Clinical Impact – Celebrating a Pioneer in Cancer Immunotherapy Dr. Sadelain received his M.D. from the University of Paris, conducted his Ph.D. research at the University of Alberta, and completed postdoctoral work at the Whitehead Institute for Biomedical Research. He previously held the Stephen and Barbara Friedman Chair at Memorial Sloan Kettering Cancer Center, where he founded the Center for Cell Engineering. As the inaugural Director of Columbia University’s Initiative in Cell Engineering and Therapy and the Columbia University Irving Medical Center’s Cancer Cell Therapy Initiative, Dr. Sadelain continues to push boundaries in cellular engineering. Dr. Sadelain’s remarkable contributions have been recognized with prestigious accolades, including the Breakthrough Prize for Life Sciences and the Canada Gairdner International Award. He is a member of the American Academy of Arts and Sciences and the National Academy of Medicine of France. With the Meyenburg Cancer Research Award, we recognize Dr. Sadelain’s outstanding efforts to improve the clinical care of cancer patients through scientific inquiry, as well as his engaging and collaborative personality.